
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this






